Glenmark Pharmaceuticals Launches Generic Kidney Cancer Medicine Axitinib in US Market

Indian Pharmaceutical Company’s US Subsidiary Introduces 1 mg and 5 mg Axitinib Tablets as Authorised Generic of Pfizer’s INLYTA

Glenmark Pharmaceuticals Limited has expanded its oncology medicines portfolio in the United States with the launch of Axitinib tablets in 1 mg and 5 mg strengths. The launch was announced on November 16, 2026, by Glenmark Pharmaceuticals Inc., USA, the American subsidiary of the Indian pharmaceutical company. The product is an authorised generic version of Pfizer’s INLYTA (axitinib), a prescription medicine used in the treatment of advanced renal cell carcinoma, a form of kidney cancer.

The introduction of Axitinib tablets represents another development in Glenmark’s international pharmaceutical business and its participation in the US market for specialised medicines. According to the company, the launch forms part of its efforts to expand access to quality and affordable medicines for patients in the United States.

The announcement was formally disclosed to the Bombay Stock Exchange and the National Stock Exchange of India on November 16, 2026.

Axitinib Used in Treatment of Advanced Kidney Cancer

Axitinib is an oral targeted therapy used in the treatment of advanced renal cell carcinoma, the most common type of kidney cancer in adults. The medicine belongs to a class of drugs known as tyrosine kinase inhibitors, which interfere with specific cellular signalling pathways involved in tumour growth and the formation of blood vessels that supply cancerous tissues.

The medicine works primarily by inhibiting vascular endothelial growth factor receptors, known as VEGFR-1, VEGFR-2 and VEGFR-3. These receptors play an important role in angiogenesis, the process through which new blood vessels are formed.

Tumours require a continuous supply of oxygen and nutrients to grow. By interfering with the signalling mechanisms responsible for blood vessel formation, axitinib helps restrict processes that support tumour development.

In the United States, axitinib is used in prescribed treatment regimens for advanced renal cell carcinoma, including certain combination therapies and treatment following earlier systemic therapy. Its use depends on the patient’s clinical condition and the treatment recommendations of qualified medical professionals.

The launch of Glenmark’s authorised generic provides another marketed version of this established oncology medicine in the United States.

Authorised Generic Version of Pfizer’s INLYTA

Glenmark’s newly launched Axitinib tablets are an authorised generic version of INLYTA, the branded medicine marketed by Pfizer Inc.

An authorised generic is a product marketed without the original brand name under the relevant regulatory arrangements. Unlike a conventional generic developed through a separate abbreviated drug application, an authorised generic is marketed under the original approved drug application with the necessary authorisation.

The product contains the same active pharmaceutical ingredient as the reference medicine and is supplied in the 1 mg and 5 mg strengths announced by Glenmark.

The company has introduced both strengths into the US market, expanding its portfolio of prescription medicines available to healthcare providers and patients.

The launch is commercially relevant because authorised generics provide an additional distribution and marketing channel for established pharmaceutical products while retaining the regulatory characteristics of the original approved medicine.

INLYTA Records $538.4 Million in Annual US Sales

According to IQVIA sales data cited by Glenmark Pharmaceuticals, INLYTA tablets recorded approximately USD 538.4 million in annual sales in the United States during the 12-month period ending September 2026.

The figures were obtained from IQVIA National Sales Perspectives, covering retail and non-retail pharmaceutical sales.

The reported sales value indicates the commercial size of the US market for the reference medicine and provides context for Glenmark’s entry into this product segment.

The USD 538.4 million figure represents historical sales of INLYTA tablets in the US market and does not constitute Glenmark’s revenue, an order value or a forecast of sales from its newly launched authorised generic.

The company has not disclosed a specific revenue target or expected market share for its Axitinib tablets.

Glenmark Highlights Access to Affordable Medicines

Commenting on the launch, Marc Kikuchi, President and Business Head, North America, Glenmark Pharmaceuticals, emphasised the company’s commitment to expanding access to medicines in the United States.

He stated that the launch of Axitinib tablets reinforces Glenmark’s commitment to making quality and affordable medicines available to American patients.

Kikuchi further highlighted that the addition of the product to Glenmark’s portfolio strengthens the company’s efforts to address the evolving requirements of patients and healthcare providers.

The announcement reflects Glenmark’s continuing emphasis on expanding its pharmaceutical portfolio through products addressing important therapeutic needs.

Expanding Glenmark’s International Pharmaceutical Portfolio

Glenmark Pharmaceuticals is an Indian research-led pharmaceutical company with operations spanning branded medicines, innovative therapies, generic pharmaceuticals and consumer healthcare products.

The company maintains an international manufacturing and research network supporting its pharmaceutical development and commercial activities.

According to Glenmark’s corporate information, the company operates 11 manufacturing facilities across four continents, supported by six research and development centres. Its commercial presence extends to more than 80 countries.

Glenmark’s principal therapeutic areas include respiratory diseases, dermatology and oncology, alongside its broader pharmaceutical portfolio.

The company’s US operations form an important component of its international business, particularly in the marketing and distribution of generic and specialised prescription medicines.

The addition of Axitinib tablets strengthens Glenmark’s participation in the American oncology pharmaceutical market and expands the range of medicines offered through its US subsidiary.

Strengthening India’s Presence in Global Pharmaceutical Markets

Indian pharmaceutical companies have established a substantial presence in international generic medicine markets, particularly in the United States.

Their participation encompasses the development, manufacturing, regulatory approval and commercialisation of medicines across numerous therapeutic categories.

Specialised pharmaceutical products, including oncology medicines, represent an important area of international market participation because they require adherence to stringent regulatory standards and established pharmaceutical quality requirements.

Glenmark’s introduction of an authorised generic of INLYTA adds another oncology medicine to the international portfolio of an Indian pharmaceutical enterprise.

The development also demonstrates the continued commercial engagement of Indian pharmaceutical companies with major international markets for established prescription medicines.

Glenmark Expands Oncology Business with US Product Launch

The launch of Axitinib tablets in 1 mg and 5 mg strengths marks another addition to Glenmark Pharmaceuticals’ US product portfolio.

The product is an authorised generic version of Pfizer’s INLYTA, an established medicine used in the management of advanced kidney cancer. Its introduction places Glenmark in a pharmaceutical product segment where the branded reference medicine recorded approximately USD 538.4 million in US annual sales during the period ending September 2026.

The launch represents a confirmed commercial development rather than a proposed product introduction or pending regulatory application.

By expanding its portfolio of specialised medicines, Glenmark continues to strengthen its international pharmaceutical operations and its participation in the US oncology market. The development reflects the growing role of Indian pharmaceutical enterprises in supplying established treatments to international healthcare markets and supporting access to prescription medicines.


Categories